New Topical Therapy for Moderate Psoriasis: An Open-Label, Pilot Study
José Miguel Ingelmo Calvo (1), José Ruiz Cobo (2), Mohamed Farouk Allam (3)*
1. Department of Plastic Surgery, Hospital HM Malaga, Malaga, Spain.
2. Distrito Sanitario Costa del Sol, SUAP Torremolinos, Malaga, Spain.
3. Department of Family
Medicine, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
International Journal of Pharmaceutical and
Phytopharmacological Research (eIJPPR) 2024;14(2):31-34.
https://doi.org/10.51847/8b1eX1xZRO
Abstract
Psoriasis
is a persistent, recurring condition characterized by numerous complications. Currently, there is no definitive cure for
psoriasis, and treatments typically provide temporary relief of symptoms.
Patent 202030824, an innovative cream for psoriasis local treatment, was issued
by the Spanish Ministry of Industry, Trade, and Tourism. This product is called
"Psorisbye," and it's a foamy lotion that contains clobetasol,
propylene glycol, spironolactone, milk-peptide complex, and papaverine
hydrochloride. We report on five cases of mild psoriasis that responded well to
our recently developed foamy lotion treatment. Our pilot study is an open-label
intervention study involving patients with moderate psoriasis. Initially, each
patient underwent a comprehensive assessment, encompassing a thorough
history-taking and clinical examination. Next, instructions were given to each
patient to use our recently developed foamy lotion once a day for a week, using
a total of 120 ml of the product during this time. The patients had a follow-up
evaluation in the outpatient clinic following a 7-day period of local
application. Every patient noted a remission of scaling lesions and claimed a
significant reduction in itching sensations. The mean pre-treatment PASI of the
patients was 20.28 (SD 6.1), while the mean post-treatment PASI was 1.8. Our
preliminary investigation indicated promising results in the treatment of
moderate psoriasis with "Psorisbye". Notwithstanding these
encouraging results, a longer follow-up is necessary to assess the length of
psoriasis remission and any possible adverse effects related to this novel topical
medication.
Key Words: Psoriasis, Topical therapy, Psoriasis area severity index, Case series, Malaga.
Calvo
JMI, Cobo JR, Allam MF. New Topical Therapy for Moderate Psoriasis: An
Open-Label, Pilot Study. Int J Pharm Phytopharmacol Res 2024;14(2):31-4. https://doi.org/10.51847/8b1eX1xZRO
